Tag: Policy + Advocacy Updates

CBSA advocates for policies that sustain innovation and create high-wage, high value jobs in life sciences, including strong intellectual property (IP) protections, which are the foundation of technol...

Congress is grappling with a busy and complex agenda before adjourning on September 27 through the election. Congress is on track to meet its deadline of October 1 to pass a government funding measure...

The newly-announced “negotiated” prices for the first ten drugs subject to price controls under the Inflation Reduction Act (IRA) are set to go into effect for people with Medicare Part D prescription...

On August 15, 2024, the Centers for Medicare & Medicaid Services (CMS) announced the new “negotiated” prices for the first ten Medicare Part D drugs subject to price controls under the Inflation R...

CBSA advocates for policies that improve patient access to life-saving, novel technologies. This August, the Centers for Medicare & Medicaid Services (CMS) released the long-awaited Transitional C...

Patients say Upper Payment Limits (UPLs) won’t make their medicines more affordable. Colorado’s Prescription Drug Affordability Board (PDAB) hasn’t listened.   Colorado’s PDAB was created to...

7/16/24  CBSA has consistently advocated for PBM reform at the state and federal level. Following the release of an interim report from the Federal Trade Commission (FTC) blasting the business pr...

On July 3, the Colorado Prescription Drug Affordability Board (PDAB or Board) voted to initiate the upper payment limit (UPL) rulemaking process for two more drugs, Stelara and Cosentyx, after deeming...

CBSA and BIO urge you to reach out to Senator Hickenlooper to encourage his support of S.4583, a bill that would reauthorize the rare pediatric disease priority review voucher (PPRV) program before it...

This past week, the CBSA team represented our community and shared our expertise on prescription drug affordability at the BIO International Convention and through a series of virtual events:  El...